[go: up one dir, main page]

CO6710913A2 - Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes - Google Patents

Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes

Info

Publication number
CO6710913A2
CO6710913A2 CO13092089A CO13092089A CO6710913A2 CO 6710913 A2 CO6710913 A2 CO 6710913A2 CO 13092089 A CO13092089 A CO 13092089A CO 13092089 A CO13092089 A CO 13092089A CO 6710913 A2 CO6710913 A2 CO 6710913A2
Authority
CO
Colombia
Prior art keywords
lysosomal lipase
lipase acid
patients
treat
deficiency
Prior art date
Application number
CO13092089A
Other languages
English (en)
Inventor
Anthony Quinn
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45806910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6710913(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of CO6710913A2 publication Critical patent/CO6710913A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de LAL humana recombinante para el tratamiento de la deficiencia de lipasa ácida lisosomal (LAL).
CO13092089A 2010-09-09 2013-04-09 Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes CO6710913A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40301110P 2010-09-09 2010-09-09
US45601410P 2010-10-29 2010-10-29
US201161432372P 2011-01-13 2011-01-13

Publications (1)

Publication Number Publication Date
CO6710913A2 true CO6710913A2 (es) 2013-07-15

Family

ID=45806910

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13092089A CO6710913A2 (es) 2010-09-09 2013-04-09 Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes

Country Status (30)

Country Link
US (6) US8663631B2 (es)
EP (3) EP3650039A1 (es)
JP (3) JP5693728B2 (es)
KR (1) KR20150038636A (es)
CN (2) CN103200958A (es)
AR (1) AR082953A1 (es)
AU (1) AU2011314293B2 (es)
BR (2) BR122019021757B1 (es)
CA (2) CA3209456A1 (es)
CL (1) CL2013000664A1 (es)
CO (1) CO6710913A2 (es)
CY (1) CY1116544T1 (es)
DK (2) DK2977057T3 (es)
ES (2) ES2769836T3 (es)
HK (2) HK1220907A1 (es)
HR (1) HRP20150438T1 (es)
HU (1) HUE048688T2 (es)
IL (2) IL225095A (es)
ME (1) ME02062B (es)
MX (2) MX2013002704A (es)
NZ (3) NZ608292A (es)
PL (2) PL2977057T3 (es)
PT (2) PT2613798E (es)
RS (1) RS53947B1 (es)
RU (1) RU2550961C2 (es)
SG (2) SG10201507199UA (es)
SI (2) SI2613798T2 (es)
SM (1) SMT201500108B (es)
TW (1) TWI482625B (es)
WO (1) WO2012050695A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60138535D1 (de) * 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PT2561069T (pt) * 2010-04-23 2017-05-22 Alexion Pharma Inc Enzima de doença de armazenamento lisossomal
CA3209456A1 (en) 2010-09-09 2012-04-19 Alexion Pharmaceuticals, Inc. Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
EP2675472A4 (en) * 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
SG10201510106PA (en) 2011-10-12 2016-01-28 Synageva Biopharma Corp Recombinant human naglu protein and uses thereof
KR20140130443A (ko) * 2012-03-02 2014-11-10 시나게바 바이오파르마, 코포레이션 절두된 리소좀 산 리파제
CN106885910B (zh) * 2015-12-15 2018-12-21 上海吉涛生物科技有限公司 肿瘤易感微环境检测装置及试剂盒
US11235036B2 (en) 2016-06-17 2022-02-01 Alexion Pharmaceuticals, Inc. Lysosomal acid lipase deficiency compositions and methods
US11155794B2 (en) 2016-08-23 2021-10-26 Alexion Pharmaceuticals, Inc. Method of purifying a heterologous protein from an egg white
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11396499B2 (en) 2018-12-12 2022-07-26 University Of Washington Lysosomal acid lipase assay
WO2021117122A1 (ja) * 2019-12-10 2021-06-17 株式会社リボルナバイオサイエンス ライソゾーム酸性リパーゼ欠損症の予防または治療剤

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
WO1992016212A1 (en) 1991-03-13 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0952841A4 (en) 1994-08-05 2000-11-02 Molecular Structural Biotechno DIRECTED BIOMOLECULAR COMPLEXES
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
EP0865499B1 (en) 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Production of lysosomal enzymes in plant-based expression systems
DK1538202T3 (en) 1996-09-13 2014-03-24 Shire Human Genetic Therapies PREPARATION OF HUMANT ALPHA-GALACTOSIDASE A
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
US20030166132A1 (en) 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1137762B1 (en) 1998-12-07 2008-10-08 Genzyme Corporation Treatment of pompe's disease
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
DE60138535D1 (de) 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2002221755A1 (en) * 2000-10-31 2002-05-15 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
US20030064437A1 (en) 2000-11-15 2003-04-03 Nick Wan Expression system for recombinant proteins
US20020193303A1 (en) 2001-01-25 2002-12-19 Millennium Pharmaceuticals, Inc. 58860, a human cholesteryl ester hydrolase and uses therefor
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
EP1476176A4 (en) 2002-01-30 2006-02-22 Univ Yale TRANSPORT PEPTIDES AND USES THEREOF
PT1495328E (pt) 2002-04-16 2014-09-09 Vlaams Interuniv Inst Biotech Um marcador para medir cirrose hepática
AU2003283976B2 (en) 2002-09-27 2009-12-10 Cold Spring Harbor Laboratory Cell-based RNA interference and related methods and compositions
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2006002053A2 (en) 2004-06-15 2006-01-05 Mayo Foundation For Medical Education And Research Helicases
JP4959566B2 (ja) 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド トランスホーミング増殖因子βファミリータンパク質の折りたたみ
US20070270367A1 (en) 2005-05-18 2007-11-22 University Of Kentucky Research Foundation Rybozyme-catalyzed insertion of targeted sequences into RNA
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
AU2006302640B2 (en) 2005-10-05 2010-08-19 Synageva Biopharma Corp. Rapid production of high titer virus
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US20070267249A1 (en) 2006-05-18 2007-11-22 Cullen David P Roof safety system
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
JP2009541211A (ja) 2006-05-24 2009-11-26 ミエリン リペア ファウンデーション， インコーポレイテッド 血液脳関門の透過性
US8143265B2 (en) 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
WO2008131431A2 (en) 2007-04-23 2008-10-30 St. Louis University Modulation of blood brain barrier protein expression
EP2164875A4 (en) 2007-05-24 2011-11-30 Us Dept Veterans Affairs INTRANUCLEAR PROTEIN TRANSDUCTION THROUGH A NUCLEOSIDE SALVAGE PATHWAY
CN101686996B (zh) 2007-05-31 2012-12-05 格莱肯生物科学公司 硫酸木聚糖在制备用于治疗或预防呼吸疾病的药物的新用途
EP2167135A2 (en) 2007-07-12 2010-03-31 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
US20100291060A1 (en) 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a
US8431770B2 (en) 2008-01-07 2013-04-30 Synageva Biopharma Corp. Method of producing sialytransferase-modified proteins
WO2010033854A2 (en) 2008-09-19 2010-03-25 Synageva Biopharma Corp. Avian derived fusion proteins
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
US8183003B2 (en) 2009-01-02 2012-05-22 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
WO2011000958A1 (en) 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
US20110033699A1 (en) 2009-07-23 2011-02-10 Nitto Denko Corporation Pressure-sensitive adhesive tape
KR101848938B1 (ko) 2009-10-19 2018-04-13 아미쿠스 세라퓨틱스, 인코포레이티드 리소좀 축적 질환을 예방 및/또는 치료하는 신규 조성물
KR101077618B1 (ko) 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
US20150030582A1 (en) 2010-04-23 2015-01-29 Synageva Biopharma Corp. Lysosomal Storage Disease Enzyme
PT2561069T (pt) 2010-04-23 2017-05-22 Alexion Pharma Inc Enzima de doença de armazenamento lisossomal
CA3209456A1 (en) 2010-09-09 2012-04-19 Alexion Pharmaceuticals, Inc. Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
WO2012112677A2 (en) 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
EP2678433B1 (en) 2011-02-22 2017-05-03 California Institute of Technology Delivery of proteins using adeno-associated virus (aav) vectors
EP2709670A4 (en) 2011-05-18 2015-01-21 Childrens Hosp Medical Center TARGETED TRANSFER OF PROTEINS OVER THE BLOOD BRAIN BARRIER
ES2664844T3 (es) 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
US20130027021A1 (en) 2011-07-28 2013-01-31 Abb Inc. Current sensor
US9676837B2 (en) 2011-08-03 2017-06-13 Shire Human Genetic Therapies, Inc. Collagen 7 and related methods
SG10201510106PA (en) 2011-10-12 2016-01-28 Synageva Biopharma Corp Recombinant human naglu protein and uses thereof

Also Published As

Publication number Publication date
US20120064055A1 (en) 2012-03-15
HK1215532A1 (zh) 2016-09-02
EP2977057A1 (en) 2016-01-27
ES2535605T3 (es) 2015-05-13
SMT201500108B (it) 2015-07-09
MX365007B (es) 2019-05-20
CA2810999C (en) 2023-10-03
EP3650039A1 (en) 2020-05-13
NZ700824A (en) 2016-03-31
KR20150038636A (ko) 2015-04-08
HUE048688T2 (hu) 2020-08-28
SI2977057T1 (sl) 2020-03-31
HK1220907A1 (zh) 2017-05-19
CA2810999A1 (en) 2012-04-19
NZ608292A (en) 2014-10-31
MX2013002704A (es) 2013-09-13
AR082953A1 (es) 2013-01-23
CA3209456A1 (en) 2012-04-19
US10166274B2 (en) 2019-01-01
ES2535605T5 (es) 2018-04-30
CN105457018A (zh) 2016-04-06
CL2013000664A1 (es) 2013-10-04
SG10201507199UA (en) 2015-10-29
DK2613798T3 (en) 2015-04-20
BR112013005673B1 (pt) 2020-12-15
SG188456A1 (en) 2013-04-30
NZ715014A (en) 2018-10-26
CN103200958A (zh) 2013-07-10
JP2013540733A (ja) 2013-11-07
ME02062B (me) 2015-05-20
US20220362350A1 (en) 2022-11-17
ES2769836T3 (es) 2020-06-29
SI2613798T1 (sl) 2015-05-29
PL2977057T3 (pl) 2020-06-01
US20190282671A1 (en) 2019-09-19
TWI482625B (zh) 2015-05-01
US20250025538A1 (en) 2025-01-23
RU2550961C2 (ru) 2015-05-20
BR122019021757B1 (pt) 2020-12-08
JP2016145257A (ja) 2016-08-12
US8663631B2 (en) 2014-03-04
PT2977057T (pt) 2020-02-18
JP2015052014A (ja) 2015-03-19
JP5693728B2 (ja) 2015-04-01
DK2977057T3 (da) 2020-02-10
SI2613798T2 (en) 2018-05-31
DK2613798T4 (en) 2018-04-16
RU2013110491A (ru) 2014-11-10
TW201225971A (en) 2012-07-01
US12076376B2 (en) 2024-09-03
CY1116544T1 (el) 2018-03-07
IL245283A0 (en) 2016-06-30
EP2613798B1 (en) 2015-02-11
WO2012050695A1 (en) 2012-04-19
EP2613798A1 (en) 2013-07-17
EP2977057B1 (en) 2019-11-06
HRP20150438T1 (hr) 2015-05-22
PL2613798T5 (pl) 2018-06-29
IL225095A (en) 2016-05-31
BR112013005673A2 (pt) 2017-09-19
JP6156882B2 (ja) 2017-07-05
EP2613798B2 (en) 2018-01-24
PL2613798T3 (pl) 2015-07-31
US20160051638A1 (en) 2016-02-25
AU2011314293B2 (en) 2015-06-04
US20140348752A1 (en) 2014-11-27
IL245283B (en) 2019-02-28
RS53947B1 (en) 2015-08-31
PT2613798E (pt) 2015-06-02
US11400141B2 (en) 2022-08-02
AU2011314293A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
PH12018500768A1 (en) Purin derivatives for use in the treatment of fab-related diseases
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
BRPI0915300B8 (pt) compostos de éster boronato e composições farmacêuticas dos mesmos
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
PT2470199T (pt) Terapia de substituição enzimática com escaladas de dose para tratamento de deficência em esfingomielinase ácida
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
BR112013004562A2 (pt) 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
CL2011002265A1 (es) Composicion farmaceutica que comprende simvastatina, enalapril y acido acetilsalicilico; uso para prevenir y tratar enfermedades cardiovasculares.
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
BR112013004690A2 (pt) 2-oxo-e 2-tioxo-di-hidroquinolina-3-carboxamidas substituídas como moduladores kcnq2/3
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
UA112981C2 (uk) Варіант людського gdnf
ECSP12012332A (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso